Bio-Path Holdings, Inc. (NASDAQ:BPTH) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in a research note published on Tuesday, StockTargetPrices.com reports. HC Wainwright currently has a $5.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Maxim Group set a $2.00 target price on Bio-Path Holdings and gave the company a buy rating in a report on Wednesday, April 5th. Zacks Investment Research raised Bio-Path Holdings from a hold rating to a buy rating and set a $0.75 target price for the company in a report on Monday, March 20th.

Shares of Bio-Path Holdings (NASDAQ:BPTH) opened at 0.4001 on Tuesday. Bio-Path Holdings has a 52-week low of $0.33 and a 52-week high of $1.89. The stock’s market cap is $38.27 million. The company’s 50-day moving average price is $0.42 and its 200-day moving average price is $0.77.

Bio-Path Holdings (NASDAQ:BPTH) last announced its earnings results on Thursday, May 11th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. Analysts expect that Bio-Path Holdings will post ($0.07) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first reported by WKRB News and is the property of of WKRB News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.wkrb13.com/markets/2285320/bio-path-holdings-inc-nasdaqbpth-given-buy-rating-at-hc-wainwright.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new position in Bio-Path Holdings during the first quarter valued at $105,000. HighTower Advisors LLC raised its position in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock valued at $1,043,000 after buying an additional 105,000 shares during the last quarter. Sabby Management LLC raised its position in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after buying an additional 23,352 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after buying an additional 5,172 shares during the last quarter. 19.88% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Stock Target Prices

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285320/bio-path-holdings-inc-nasdaqbpth-given-buy-rating-at-hc-wainwright.html

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.